Table 1.
Patient and donor characteristics in the retrospective study
| Characteristics | All patients | MSDT | HBMT | ||||
|---|---|---|---|---|---|---|---|
| MRDneg | MRDpos | MRDneg | MRDpos | ||||
| Number of patients | 339 | 85 | 14 | 189 | 51 | ||
| Median age (range), years | 31 (2–60) | 41 (12–57) | 44 (5–57) | 0.457 | 27 (2–60) | 28 (9–57) | 0.151 |
| Weight (range), kg | 61 (15.5–118) | 66.5 (29–97) | 68 (23–96) | 1.000 | 64 (15.5–118) | 60 (25–102) | 0.286 |
| Male, n (%) | 165 (48.7%) | 41 (48.2%) | 9 (64.3%) | 0.263 | 96 (50.8%) | 19 (37.3%) | 0.086 |
| Diagnosis, n (%) | 0.264 | 0.031 | |||||
| De novo AML | 333 (98.2%) | 84 (98.8%) | 13 (92.9%) | 188 (99.5%) | 48 (94.1%) | ||
| Secondary AML | 6 (1.8%) | 1 (1.2%) | 1 (7.1%) | 1 (0.5%) | 3 (5.9%) | ||
| Disease status, n (%) | 0.217 | 0.137 | |||||
| CR1 | 301 (88.8%) | 81 (95.3%) | 12 (85.7%) | 167 (88.4%) | 41 (80.4%) | ||
| CR > 1 | 38 (11.2%) | 4 (4.7%) | 1 (14.3%) | 22 (11.6%) | 10 (19.6%) | ||
| FLT3-ITD mutation | 0.302 | 0.582 | |||||
| Yes | 20 (5.9%) | 5 (5.9%) | 2 (14.3%) | 11 (5.8%) | 2 (3.9%) | ||
| No | 319 (94.1%) | 80 (94.1%) | 12 (85.7%) | 178 (94.2%) | 49 (96.1%) | ||
| Cytogenetics | 0.247 | 0.285 | |||||
| Favorable | 59 (17.4%) | 16 (18.8%) | 1 (7.1%) | 30 (15.9%) | 12 (23.5%) | ||
| Intermediate | 263 (77.6%) | 65 (76.5%) | 13 (92.9%) | 150 (79.4%) | 35 (68.6%) | ||
| Adverse | 17 (5.0%) | 4 (4.7%) | 0 | 9 (4.8%) | 4 (7.8%) | ||
| Conditioning regimen, n (%) | |||||||
| MA | 339 (100%) | 85 (100%) | 14 (100%) | 189 (100%) | 51 (100%) | ||
| HLA-A-, B-, and DR-mismatched grafts, n (%) | 0.245 | ||||||
| 0 | 101 (29.8%) | 85 (100%) | 14 (100%) | 1 (0.5%) | 1 (2.0%) | ||
| 1 | 14 (4.1%) | 0 | 0 | 13 (6.9%) | 1 (2.0%) | ||
| 2 | 55 (16.2%) | 0 | 0 | 40 (21.2%) | 15 (29.4%) | ||
| 3 | 126 (49.9%) | 0 | 0 | 135 (71.4%) | 34 (66.7%) | ||
| Donor-recipient sex-matched grafts, n (%) | 0.249 | 0.481 | |||||
| Male–male | 104 (30.7%) | 22 (25.9%) | 4 (28.6%) | 62 (32.8%) | 16 (31.4%) | ||
| Male–female | 86 (25.3%) | 25 (29.4%) | 1 (7.1%) | 55 (29.1%) | 14 (27.5%) | ||
| Female–male | 95 (28.0%) | 32 (37.6%) | 8 (57.1%) | 44 (23.3%) | 8 (17.6%) | ||
| Female–female | 47 (13.9%) | 6 (7.1%) | 1 (7.1%) | 28 (14.8%) | 12 (23.5%) | ||
| Donor-recipient relationship, n (%) | 0.439 | ||||||
| Parent–child | 128 (37.8%) | 0 | 0 | 104 (55.0%) | 24 (47.1%) | ||
| Sibling–sibling | 176 (51.9%) | 85 (100%) | 14 (100%) | 58 (30.7%) | 19 (37.3%) | ||
| Child–parent | 32 (9.4%) | 0 | 0 | 24 (12.7%) | 8 (15.7%) | ||
| Other | 3 (0.9%) | 0 | 0 | 3 (1.6%) | 0 (0%) | ||
| ABO matched grafts, n (%) | 0.087 | ||||||
| Matched | 201 (59.3%) | 53 (62.4%) | 9 (64.3%) | 0.345 | 104 (55.0%) | 35 (68.6%) | |
| Major mismatch | 62 (18.3%) | 19 (22.4%) | 1 (7.1%) | 39 (20.6%) | 3 (5.9%) | ||
| Minor mismatch | 58 (17.1%) | 9 (10.6%) | 2 (14.3%) | 36 (19.0%) | 11 (21.6%) | ||
| Bi-directional mismatch | 18 (5.3%) | 4 (4.7%) | 2 (14.3%) | 10 (5.3%) | 2 (3.9%) | ||
| EBMT score, n (%) | 0.063 | 0.850 | |||||
| 0 | 0 | 0 | 0 | 0 | 0 | ||
| 1 | 73 (21.5%) | 23 (27.1%) | 3 (21.4%) | 38 (20.1%) | 9 (17.6%) | ||
| 2 | 156 (46.0%) | 50 (58.8%) | 7 (50.0%) | 78 (41.3%) | 21 (41.2%) | ||
| 3 | 76 (22.4%) | 11 (12.9%) | 1 (7.1%) | 50 (26.5%) | 14 (27.5%) | ||
| 4 | 25 (7.4%) | 1 (1.2%) | 2 (14.2%) | 18 (9.5%) | 4 (7.8%) | ||
| 5 | 9 (2.7%) | 0 | 1 (7.1%) | 5 (2.6%) | 3 (5.9%) | ||
| Cell compositions in allografts | |||||||
| Infused nuclear cells, (range) 108/kg | 7.51 (3.98–16.77) | 7.51 (3.98–14.75)(5.18–14.93) | 7.12 (5.78–12.75) | 0.896 | 7.40 (4.32–16.77) | 7.69 (5.4–14.07) | 0.262 |
| Infused CD34+ cells, (range) 106/kg | 2.32 (0.50–9.78) | 2.26 (0.76–9.78) | 2.05 (1.16–5.04) | 0.670 | 2.32 (0.50–9.47) | 2.46 (1.04–8.80) | 0.448 |
| DLI after transplant, n (%) | |||||||
| For relapse prophylaxis and intervention | 28 (8.3%) | 6 (7.1%) | 4 (28.6%) | 0.046 | 13 (6.9%) | 5 (9.8%) | 0.686 |
| For relapse treatment | 19 (5.6%) | 2 (2.4%) | 2 (14.3%) | 0.171 | 12 (6.3%) | 3 (5.9%) | 0.902 |
Abbreviations: HLA human leukocyte antigen, MSDT HLA-matched sibling donor transplantation, HBMT unmanipulated haploidentical blood and marrow transplantation, MRD minimal residual disease, neg negative, pos positive, AML acute myeloid leukemia, CR complete remission, MA myeloablative regimen, EBMT European Group for Blood and Marrow Transplantation, DLI donor lymphocyte infusions